Nutrivert will develop both Animal and Human applications of Nutrivert LDPP.

Animal Health
The animal version of Nutrivert LDPP will be presented as a 50 lb or 20 kg bag of medicated feed premix. The product will be suitable for blending with other feed ingredients and offers a lower cost solution to producers. Nutrivert LDPP for animals is thermostable and will be pelletable.

A cGMP manufacturing process is under development by Syngene, under contract. The facility, which is FDA-approved, is likely to be the manufacturing site. 

Composition of Matter and Methods of Use patents have been filed in all major countries via the PCT process.

Human Health
Pre-treatment with Nutrivert LDPP at low oral doses provided potent prophylaxis and relief from symptoms of two viral respiratory diseases in pigs: 86% protection from mortality caused by porcine reproductive and respiratory syndrome virus (PRRSV) and complete protection from disease (at highly reduced fever) caused by influenza A, a flu strain that also infects humans. We will evaluate, for human use, a low dose oral medication and a slow-release injectable formulation designed to offer 30-day protection against flu and potentially other viral respiratory diseases.